Objective. Patients with OA use different drugs in their search for relief. We aimed to study the prevalence of use and combinations of different medications for OA in a population-based cohort of OA patients in Catalonia, Spain, while characterizing users of each of the drugs available, with a particular focus on cardiovascular risk factors.
Introduction
OA has a great impact on patients' quality of life and productivity, as well as on health care costs, with current predictions suggesting that OA will be the fourth leading cause of disability by the year 2020 [1] . A recent epidemiological study on the health burden of 291 different conditions places OA among the top 25 causes with the greatest impact on health worldwide [2] .
It has also been shown that OA leads to increased morbidity, with strong associations with metabolic syndrome, diabetes and walking disability [3] , and a recent study showed an increased risk of death (mainly of cardiovascular causes) among OA patients [4] . Joint replacement surgery for OA represents a large economic burden: according to data from the UK National Joint Registry, 9095% of the total number of knee/hip arthroplasties carried out nationally are due to OA [5] .
Several medication therapies are available to reduce OA-associated symptoms, but consensus on therapeutic strategies is inadequate and guidance on first-line therapies is poorly implemented. This leads to great variability in the use of different drugs for OA, with unknown consequences for health care costs and patient safety [6] . A number of these drugs are associated with increased cardiovascular events in a population that is likely to have a high cardiovascular risk profile [4] .
We aimed to study the prevalence of use of different medications (and drug combinations) for OA in a population-based cohort of OA patients in Catalonia, Spain, and to characterize users of each of the drugs available, with a particular focus on cardiovascular risk factors. Finally, we estimated the incidence of the use of each of these drugs among newly diagnosed OA patients in the first year following the date of their diagnosis.
Methods

Source of data
Data for this study were obtained from the Sistema d'Informació per al Desenvolupament de l'Investigació en Atenció Primà ria (SIDIAP) database. SIDIAP comprises electronic medical records of patients registered in any of the 274 participating primary health care practices in Catalonia, covering a population of 5 million patients (70% of the Catalonian population in 2006) and with a total of 3414 participating general practitioners. SIDIAP encompasses the clinical and referral events registered in primary care medical records, comprehensive demographic information, prescriptions, referrals and laboratory test results and has recently been validated for OA [7, 8] . Health professionals gather this information using International Statistical Classification of Diseases and Related Health Problems (ICD) 10 codes for symptoms and co-morbidities and structured spreadsheets designed for the collection of clinical and administrative variables, including country of origin, gender, age, BMI, smoking status and drinking status. Encoding personal and clinic identifiers ensures the confidentiality of the information in the SIDIAP database. SIDIAP is fully linked to the official pharmacy invoice database (Facturació CatSalut Institut Català de la Salut), which was the source of data on drug utilization for the current study.
Study population
All participants registered in SIDIAP and aged 540 years on 1 January 2006 were eligible (n = 3 266 826). Participants with a prevalent or incident diagnosis of OA (ICD codes M15 for polyarticular OA, M18 and M15.215.2 for hand OA, M16 for hip OA, M17 for knee OA, M47.847.9 for spine OA and M19 for unspecific OA) in the study period (200610) constituted the study population. Patients with a history of any inflammatory arthritis were excluded.
Variables of interest
Patient characteristics
Study participants were characterized at baseline (date of OA diagnosis) according to age, gender, BMI, joints affected, common co-morbidities and cardiovascular risk factors (chronic obstructive pulmonary disease, hypertension, type 2 diabetes and history of ischaemic heart disease and/or cerebrovascular disease).
Medications used
Information on drug utilization was retrieved from the official pharmacy invoice database and classified using the Anatomical Therapeutic Chemical (ATC) system (World Health Organization Collaborating Centre for Drug Statistics Methodology [9] ). The list of ATC codes used is presented in supplementary Table S1 , available at Rheumatology Online, and covers all the drugs with an indication for OA (according to current guidelines [1014] ) subsidized by the Spanish national health system in the study period. This includes oral NSAIDs, topical NSAIDs, paracetamol (alone and in combination with other drugs), cyclooxygenase 2 (COX-2) inhibitors, the three symptomatic slow-acting drugs in OA (SYSADOA) subsidized by the Spanish health system (chondroitin sulphate, glucosamine sulphate and diacerein), other common non-narcotic analgesics (metamizole) and the most commonly used narcotic analgesics in the data (tramadol and fentanyl).
Prevalence of use
Drug utilization was described in terms of prevalence of use (any number of doses at any time during follow-up), incidence of new use (only among patients with a new diagnosis of OA in the study period) and quantitative use. Drug combinations were defined as the concomitant use of different drugs in the same calendar year. For the study of prevalence, a patient was defined as a prevalent user of a particular drug if he/she filled at least one prescription for that drug at any time during the observation period. The denominator of prevalence estimates included both prevalent and incident OA patients. Quantitative use of each different medication (except topical NSAIDs) was described using medication possession ratios (MPRs). The MPR is a standard measurement that is defined as the number of days for which medication is available (number of daily defined doses as defined by the ATC classification) divided by the number of days of treatment (time from first to last prescription) [15] . Regular use of a certain medication was defined as an MPR of 550% and occasional use as an MPR of 525%.
Trends in drug use among newly diagnosed OA patients
For the study of the annual incidence of use of a particular drug in 200610, a participant was defined as a new (incident) user of that drug if he/she started using the drug of interest (any number of doses) in the first year after he/she was diagnosed with OA, having filled no prescriptions for www.rheumatology.oxfordjournals.org that same drug in the previous year. Thus the denominator of incidence estimates included only patients with an incident diagnosis of OA in the index year.
Statistical analyses
Number and prevalence (99% CI) of users of each of the drugs of interest and drug combinations were estimated in the entire study population (both prevalent and incident OA patients). The most commonly used drug combinations (in chronological order of prescription following incident OA diagnosis) were established. Patient baseline characteristics for each drug user group (based on prevalence of use) were described using descriptive statistics.
A Poisson distribution was assumed to estimate the incidence of new drug users and corresponding 99% CIs for each of the drugs of interest in annual intervals (2006, 2007, 2008, 2009 and 2010) only among newly diagnosed OA patients in each index year.
This study follows the national and international ethics principles stated in the Declarations of Helsinki and Tokyo. This study was approved by the SIDIAP Scientific Committee and the local ethics committee (CEIC IDIAP JordiGol). Confidentiality of data is ensured by coding individuals, as required by the Spanish Law for Data Protection and Confidentiality (15/1999, 13 December, Protecció n de Datos de Cará cter Personal).
Results
Over the 5 year observation period, a total of 238 536 individuals were diagnosed with OA and included in these analyses. The cohort had a mean age of 67.0 years (S.D. 12) and 80 340 (33.7%) were male. A total of 72 887 (40.8% of those with a BMI available) were defined as overweight (BMI 25 to <30 kg/m 2 ) and 77 119 (43.1%)
were obese (BMI 530 kg/m 2 ) at the time of OA diagnosis.
Of those with a diagnosis of OA, the most common joints affected were the knee [n = 96 222 (40. Table S2 , available at Rheumatology Online. Users of SYSADOAs were youngest, while those using tramadol were oldest. SYSADOA users showed a higher prevalence of knee and hand OA, while tramadol users had the highest prevalence of hip and polyarticular OA. Tramadol users were those most commonly affected by all the comorbid conditions studied. Interestingly, cardiovascular risk factors were frequent among users of COX-2 inhibitors and NSAIDs, with prevalence of >50% and 17% for hypertension and type 2 diabetes, respectively.
The prevalence of use of each of the drugs studied and the most common drug combinations are displayed in Table 2 . More than half of the patients had at least three drugs in a single year [n = 128 655 (53.9%)], while only a few patients were exposed to either one [n = 34 766 (14.6%)] or none [n = 14 339 (6.0%)] of the drugs studied. The most common two-medication drug regimens were (in order) oral NSAIDs + analgesics, topical NSAIDs + analgesics and SYSADOAs + oral NSAIDs.
In chronological order, 50.4% (n = 120 271) of the patients started analgesics, 32.4% (n = 77 270) oral NSAIDs and 9.1% (n = 21 819) topical NSAIDs as first-line treatments after an OA diagnosis. Among those who started analgesics first, oral NSAIDs in second place followed by opioids in third place constituted the most common drug chronology. Similarly, analgesics and oral NSAIDs were the most commonly prescribed second-line medication groups following initial oral NSAIDs and analgesics, respectively, and opioids were the most prescribed thirdline medication in both groups. Detailed results on drug chronologies are described in Table 3 .
Quantitative drug utilization is illustrated in Table 4 , where the percentages of individuals defined as regular users (MPR 550%) and occasional users (MPR 525%) for each drug group are presented. The highest prevalence of regular users was for chondroitin sulphate (21.2%), followed by glucosamine sulphate (15.8%) and oral NSAIDs (14.4%). Conversely, the lowest percentages of regular users were seen for metamizole (0.68%), paracetamol in combination (0.75% with tramadol, 0.41% with other drugs) and fentanyl (0.22%).
The annual incidence of use for the different medications among newly diagnosed OA patients is displayed in Figs. 1 and 2 . Fig. 1 shows the incidence of all analgesic 
Discussion
This study describes the use of various prescribed medications among patients with clinically diagnosed OA in a 5 year period in Catalonia, Spain. We show patterns of use of different groups of drugs commonly indicated for OA according to patient characteristics. Oral NSAIDs and paracetamol were the drugs most widely used in this population, with almost 80% and 75%, respectively, of individuals having used them at some point. Opioids were most used among the oldest patients with hip and polyarticular OA, while SYSADOA use was more prevalent in the younger groups, and particularly in patients with knee and hand OA. Drug combinations are very common in OA patients, with >80% using two or more of these drugs and more than half using at least three simultaneously. Analgesics, oral NSAIDs and topical NSAIDs (in that order) are the most commonly used first-line treatment, with oral NSAIDs and analgesics being the most commonly added second drug and opioids being the most frequent third-line therapy. Quantitative utilization appears to be poor for all these drugs, with >98% of metamizole and opioid users (including combinations with paracetamol) having low drug use (<25% MPR). NSAIDs, paracetamol, chondroitin sulphate, glucosamine and COX-2 inhibitors were regularly used (MPR 550%) by >10% of the total number of users of each of these drugs. This rose to >20% for chondroitin sulphate.
We also report trends of initiation of each of these therapies in the period 200610. The incidence of new indications of oral and topical NSAIDs and paracetamol have decreased by 6%, 12% and 7%, respectively, in this period. In contrast, we observed a continuously incremental initiation of opioids and COX-2 inhibitors. Opioid initiation increased steadily and reached a 26% increase overall, while the incidence of new COX-2 inhibitor therapy experienced a rapid rise of 11-fold in the first 3 years after commercialization, followed by a slower but still significant increase of 25% in the last 2 years. The three SYSADOA drugs we studied showed two different patterns: the number of new users of chondroitin sulphate increased by almost 60% in the 5 year period, while glucosamine and diacerein initiation rates both decreased by 50%.
Paracetamol is recommended as the first-line pharmaceutical therapy to treat OA symptoms, [10, 12] while oral NSAIDs are widely recommended for OA subjects with moderate to severe joint pain [16] . It is therefore surprising to find paracetamol in second position of the most prescribed drugs following oral NSAIDs. Oral NSAID use has been associated with increased risk of cardiovascular events, even in short-term therapy [17] . This is particularly relevant for OA patients, who are a population already at high risk for cardiovascular events (>50% had hypertension and >17% had type 2 diabetes in our data).
This study is comparable to a recent Canadian cohort of community-dwelling persons aged 555 with hip or knee OA that reported that OA medication varied by age and gender, independent of disease and medical and social context [18] .
Different trends in the use of medications in OA are reported here, with the use of the most common drugs (paracetamol, NSAIDs) decreasing with time and only three drugs increasing during the study period: opioids, chondroitin sulphate and COX-2 inhibitors. The reasons for an increase in the use of opioids in OA are not clear, but ageing and increasing obesity, which are associated with increased risk of cardiovascular disease and bleeding, [19] could explain this finding. Physicians are possibly prescribing opioids to patients with more co-morbidities aiming to minimize safety issues. However, this might be a false belief, as opioid use has been related to a higher risk of several serious side effects when compared with oral NSAIDs in elderly patients with OA, including allcause hospitalization, cardiovascular events and a >4-fold higher risk of fractures [20] . This is clinically meaningful, as a recent multinational study proved that patients with OA have an increased risk of falls and fractures [21] . In addition, we expected the annual incidence of new users of COX-2 inhibitors to decrease after 2008, following the publication of results showing an increased risk of serious cardiovascular events related to these therapies [11, 13] , but rates continued to increase in the last 2 years of our study (200910) .
Any evidence on the safety and efficacy of these drugs in randomized clinical trials must be viewed with caution when applied to actual practice conditions, as drug utilization appears to be much lower than in experimental settings. From our data, only chondroitin sulphate and topical NSAIDs were used regularly (MPR 550%) by at least 20% of the users of these drugs, while the proportion of regular users remained somewhere between 10% and 20% for the most common drugs, including oral NSAIDs, COX-2 inhibitors and paracetamol. Use of opioids is particularly low, including both weaker (tramadol) and stronger (fentanyl) derivatives, consistent with current recommendations. According to the Osteoarthritis Research Society International recommendations, opioids should be limited in time and surgical treatment should be considered for patients who need them [13] . Furthermore, it is recommended that non-tramadol opioids should rarely be used, even if OA pain is severe [22] . The very low use of metamizole might suggest that this is primarily used as a rescue medication for flare symptoms.
Strengths and limitations
This study is unique due to the population size, scope of medications and 5 year time span. One of the major strengths of this study is that diagnosis and severity of OA have been validated, as OA coding in SIDIAP has been shown to be highly specific in previous studies [8, 21] . Also, NSAIDs and some analgesics (such as paracetamol alone) can be acquired over the counter in Spain, likely explaining our findings on low drug utilization of these medications. However, all the drugs studied are subsidized in Spain, and patients aged 565 years get them free of charge, which might minimize this issue. It is likely that there is a good proportion of individuals with mild to moderate OA in our cohort, since the patients were collected in primary care practice settings. However, this is representative of the overall OA population, and the fact that this information was gathered in actual practice conditions improves its generalizability.
Conclusions
We conclude that the use of different medications for OA varies with patient characteristics: oral NSAIDs, COX-2 inhibitors and opioids are widely used among elderly OA patients, which may lead to serious side effects, including cardiovascular events and fractures. However, the quantitative utilization of these therapies is low, making it difficult to translate findings from clinical trials into actual practice regarding safety and efficacy. In addition, drug combinations are very common among these patients, and more data on potential drug interactions are urgently needed. The incidence of new users of paracetamol and oral NSAIDs has decreased in the last 5 years, while the use of SYSADOAs has remained stable overall and the use of opioids and COX-2 inhibitors has increased. Our findings should alert clinicians to the potential unnecessary costs and iatrogenic effects in the management of patients with OA.
Rheumatology key messages
. Oral NSAIDs and opioids are the most common medications among elderly OA patients. . Drug combinations in treating OA are common and more data on potential drug interactions are needed.
